New research shows that the CoREST complex controls the acquisition of endocrine therapy resistance in estrogen receptor-positive breast cancers. Profiling data show that this resistance transition is accompanied by a functional retargeting of CoREST on chromatin in coordination with cJUN and SWI/SNF (cBAF).
This is a preview of subscription content, access via your institution
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 per month
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Get just this article for as long as you need it
Prices may be subject to local taxes which are calculated during checkout
Siegel, R. L., Miller, K. D. & Jemal, A. CA Cancer J. Clin. 70, 7–30 (2020).
American Cancer Society. Breast Cancer Facts & Figures 2019–2020 (2019).
Patten, D. K. et al. Nat. Med. 24, 1469–1480 (2018).
Griffith, O. L. et al. Nat. Commun. 9, 3476 (2018).
Garcia-Martinez, L. et al. Nat. Commun. 12, 1786 (2021).
Yomtoubian, S. et al. Cell Rep. 30, 755–770 (2020).
Deblois, G. et al. Cancer Discov. 10, 1312–1329 (2020).
Garcia-Martinez, L. et al. Nat. Struct. Mol. Biol. https://doi.org/10.1038/s41594-022-00856-x (2022).
Song, Y. et al. Cell Rep. 30, 2699–2711 (2020).
Mazumdar, S. et al. PLoS ONE 10, e0121281 (2015).
Kalin, J. H. et al. Nat. Commun. 9, 53 (2018).
Vinckier, N. K. et al. Nat. Commun. 11, 2082 (2020).
Vierbuchen, T. et al. Mol. Cell 68, 1067–1082 (2017).
Lin, R. et al. Cell Biosci. 12, 89 (2022).
Gao, F. et al. Mol. Cell 75, 891–904 (2019).
B.Y.C. and D.C.H. are supported by US National Institutes of Health grants 5T32GM133351 (B.Y.C), R01 CA228211 (D.C.H.), the Pew-Stewart Scholars for Cancer Research (D.C.H.) and the American Cancer Society Research Scholar Award (D.C.H.)
The authors declare no competing interests.
Rights and permissions
About this article
Cite this article
Chick, B.Y., Hargreaves, D.C. Switching under selection: how CoREST controls endocrine therapy resistance in ER+ breast cancer. Nat Struct Mol Biol 29, 1040–1042 (2022). https://doi.org/10.1038/s41594-022-00858-9